MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/ftox.2026.1740791

Медицинская библиотека · Frontiers in toxicology · 2026

AI-enhanced clinical trial-in-a-dish platform for improved DILI risk classification and mechanistic insights into hepatotoxicity.

Cherradi Sara, Roux Salomé, Bailleux Caroline, Devic Clément, Debaigt Colin, Guerda Kamelia, Luciano Samantha, Dalle Mélanie, Duong Hong Tuan

СтатьяПеревод в очереди

Аннотация

Drug-induced liver injury (DILI) remains a leading cause of clinical trial attrition and post-marketing drug withdrawals. Its prediction is hindered by the limited physiological relevance and interindividual variability captured in conventional preclinical models. To overcome this, we developed a human serum-derived educated spheroid system incorporating human blood sera from donors to generate liver spheroids that recapitulate human hepatic diversity. This platform enables clinical trial-in-a-dish studies and supports acute and chronic treatment regimens. Using a panel of drugs spanning the full DILI risk spectrum, we evaluated hepatotoxic potential through a proprietary AI-driven algorithm that integrates severity and incidence metrics at therapeutic concentrations. Our platform reliably distinguished low-risk from high-risk DILI compounds and recapitulated both dose-dependent and idiosyncratic toxicity profiles. Notably, ximelagatran-induced DILI was only detected under chronic exposure conditions, mirroring clinical outcomes. Transcriptomic profiling revealed innate immune activation in DILI-positive individuals. STRING analysis further implicated HLA-DRB1 and HLA-DQA1 interactions via VIM upregulation in macrophages and dendritic cells, suggesting a mechanistic link to immune-mediated iDILI. In exploratory prospective studies, our system predicted ribociclib-induced grade 3 DILI in one ER+/HER2- breast cancer patient and absence of DILI in two patients, consistent with clinical outcomes. These findings highlight the value of integrating our model with our AI-based mapping strategy to enable mechanistic classification of DILI, deconvolution of immune-related toxicity, and prediction of patient-specific risk. Our platform represents a step toward personalized hepatotoxicity assessment and improved translational toxicology strategies.

Для цитирования: Cherradi Sara, Roux Salomé, Bailleux Caroline, Devic Clément, Debaigt Colin, Guerda Kamelia, Luciano Samantha, Dalle Mélanie, Duong Hong Tuan. AI-enhanced clinical trial-in-a-dish platform for improved DILI risk classification and mechanistic insights into hepatotoxicity.. Frontiers in toxicology. 2026. DOI: 10.3389/ftox.2026.1740791.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.